Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 186 publications
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.
Journal: Leukemia & lymphoma
Published: July 29, 2026
Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 15, 2026
Weakened macrophage antibacterial capacity in myelodysplastic syndrome.
Journal: ImmunoHorizons
Published: June 03, 2026
RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.
Journal: Blood cancer discovery
Published: May 01, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.
Journal: Blood cancer discovery
Published: May 01, 2026
Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic Leukemia.
Journal: European journal of haematology
Published: March 19, 2026
A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia.
Journal: Blood advances
Published: February 20, 2026
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma.
Journal: bioRxiv : the preprint server for biology
Published: January 23, 2026
The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.
Journal: bioRxiv : the preprint server for biology
Published: January 07, 2026
The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells.
Journal: Blood cancer discovery
Published: December 29, 2025
Last Updated: 09/26/2026